InSightec launches ExAblate One and ExAblate OR systems at CIRSE 2010

210

InSightec announced that it will be launching ExAblate One for the treatment of uterine fibroids, adenomyosis and research options in women’s health and the ExAblate OR system as the operating room of the future at the upcoming Cardiovascular and interventional radiological society of Europe (CIRSE) 2010 meeting.

The ExAblate family of systems employs focused ultrasound to non-invasively heat and destroy targeted tissue under MR guidance. The MRI system, identifies and targets tumours, while providing real time temperature monitoring of the treated tissue.

With experience in treating over 6000 patients at more than 80 centres around the world, the ExAblate family of systems offers a proven and mature platform for commercially approved treatments as well as research options for a wide range of clinical indications.

 

Innovative ExAblate One expands treatment choices for women suffering from uterine fibroids and adenomyosis. Recent advances in ExAblate technology now enable the treatment of large and vascular fibroids as well as adenomyosis, broadening the patient base. The ability to treat greater fibroid volumes is expected to result in greater clinical efficacy. ExAblate significantly improves adenomyosis symptoms, and in many cases can improve a patient’s chances of overcoming infertility caused by the condition.

 

Patients treated for uterine fibroids or adenomyosis typically return to their normal routine within twenty four hours of the procedure, a major improvement over most fibroid treatment techniques. A growing number of women have become pregnant following the ExAblate treatment. Studies have shown that MR guided focused ultrasound (MRgFUS) may even improve fertility in women suffering from infertility caused by uterine fibroids.

 

Experience at sites around the world has shown that ExAblate significantly increases patient interest in MRgFUS treatment and facility traffic. A leading site in Tokyo, Japan reported that the number of patients treated for uterine fibroids increased by 550% in one year.

 

The ExAblate treatment has also been proven as a cost-effective alternative to current treatments, meeting acceptable criteria for optimal cost-effectiveness in fibroid treatment.

 

“MR guided focused ultrasound use in the treatment of uterine fibroids has been an accepted and viable option for increasing numbers of women for several years now. However, with the enhancements offered by ExAblate One we are able to offer even more women the option of treatment with an effective, dedicated women’s health platform with predictable results.” Said prof. Wladyslaw M Gedroyc. “In addition to the benefits to patients, such as preservation of the uterus and improved chances of fertility, we have also seen a significant reduction in treatment time.”

 

 

The ExAblate OR platform is a non-invasive image guided and controlled acoustic operating room. The system incorporates interchangeable cradles for each application that are interfaced with a single common table. ExAblate OR offers both commercially approved and research treatment options for a multitude of clinical indications such as: uterine fibroids and adenomyosis, breast cancer, prostate cancer, pain palliation of bone metastases and various other indications.

 

ExAblate One and ExAblate OR are compatible with both GE Healthcare’s Signa and Discovery MRI product lines and have a newly designed patient bed with ergonomic advantage for patients, streamlined user interface and improved usability for physicians.